Abstract 782
Background
Cell fusion (CF) is a normal biological process that plays major role in mammalian development and differentiation. Through CF, somatic cells acquire nuclear reprogramming and epigenetic modifications to form pluripotent hybrid cells, which constitute an efficient process of rapid evolution to generate hybrids with new genetic, phenotypic and functional properties at a rate exceeding that achievable by random mutagenesis. Experimental and clinical evidences indicate that CF occurs in solid tumors and contribute to cancer progression by generating progeny with metastatic features and resistance to oncologic treatments. Phosphatidylserine (PS) is a glycerophospholipid, recognized by CD36 receptor in macrophage to detect apoptotic cells. The PS-CD36 interaction is a crucial step in fusion between monocytes and tumor cells. The aim of this study is to investigate the impact of the PS-CD36 expression in macrophage–cancer cell fusion and in relation to ionizing radiation (IR).
Methods
GFP-labeled breast cancer MCF-7 cells and macrophages (differentiated monocyte cell line THP-1) were used in CF in vitro experiment with IR (figure 1). MCF-7/macrophage hybrids were generated by spontaneous CF, isolated by fluorescence activated cell sorting and confirmed by fluorescence microscopy. We treated the hybrids and their maternal cells (MCF-7 and macrophages) with IR (ɣ-irradiation, 0Gy, 2.5Gy and 5Gy). Anti-CD36 antibody, 40µg and 80µg, was used to block CD36 receptor. CF rate is based on the number of seeded macrophages, since they do not proliferate. The proportion of hybrids = (number of hybrids/number of seeded macrophages in same sample) x100.
Results
IR induces the exposure of PS (dose dependent) on MCF-7 cells, which was not found in macrophages. IR also induces significant expression of CD36 in THP-1 cells. CF was inhibited by blocking of CD36 receptor with anti-CD36 antibodies (figure 2).
Conclusions
IR induces macrophage-cancer cell fusion by stimulating the exposure of PS on MCF-7 cells and the expression of CD36 in macophages. CF and the generation of metastatic hybrids can be prevented by inhibiting the PS-CD36 interaction, a mechanism constituting an essential step in macrophage-cancer CF.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ivan Shabo, Karolinska Institutet, Stockholm Sweden.
Funding
Swedish Society of Medicine.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5995 - Invasive fungal diseases caused by rare pathogens in patients after hematopoietic stem cell transplantation (HSCT) & chemotherapy
Presenter: Yuliya Rogacheva
Session: Poster Display session 1
Resources:
Abstract
2961 - Safety and pharmacokinetics of novel CXCR4 antagonist YF-H-2015005 in the mobilization of hematopoietic stem cells in patients with non-Hodgkin's lymphoma
Presenter: Weiping Liu
Session: Poster Display session 1
Resources:
Abstract
5771 - Chemotherapy associated Hyponatremia in Hematological Malignancies: A retrospective study of 189 patients treated in a single medical center
Presenter: Vadim Lesan
Session: Poster Display session 1
Resources:
Abstract
1165 - Risk factors for Bacteremia-Associated Mortality of Aeromona sobria in Hematologic Malignancies
Presenter: Gabriel De la Cruz-Kú
Session: Poster Display session 1
Resources:
Abstract
5287 - Use of droplet digital polymerase chain reaction for detecting minimal residual disease: a prospective, multi-institutional study
Presenter: Hyunkyung Park
Session: Poster Display session 1
Resources:
Abstract
1886 - RUBIH2 — Use of NGS in haematological malignancies: from real world data to national recommendations, an innovative program to evaluate the impact of healthcare technology on patient care
Presenter: Severine Coquerelle
Session: Poster Display session 1
Resources:
Abstract
1940 - Outcomes of chronic myeloid leukemia with T315I mutation in the absence of targeted therapy or hematopoietic stem cell transplantation
Presenter: Nageswara Palukuri
Session: Poster Display session 1
Resources:
Abstract
1946 - Is bone marrow examination indispensible in chronic myeloid Leukemia at diagnosis ?
Presenter: Nageswara Palukuri
Session: Poster Display session 1
Resources:
Abstract
1904 - Incidence of Imatinib Resistance in Chronic Myeloid Leukemia (CML) Patients: Experience from Resource Poor Centre of Eastern India
Presenter: Debmalya Bhattacharyya
Session: Poster Display session 1
Resources:
Abstract
3245 - BCR-ABL transcript variant’s significance in chronic myeloid leukemia in chronic phase: Institutional experience from a developing country
Presenter: Siva Prasad
Session: Poster Display session 1
Resources:
Abstract